
National Skin Centre launches vitiligo data collection in Southeast Asia
The centre plans to enrol up to 500 patients in the programme.
Singapore's National Skin Centre (NSC), a specialist dermatological centre under NHG Health, has begun a real-world data collection initiative on vitiligo in Southeast Asia.
NSC plans to enrol up to 500 patients in the programme to evaluate the efficacy and safety of Ruxolitinib cream.
“Current studies on the effectiveness of Ruxolitinib are conducted mainly on Western populations; hence, experience on the effectiveness of the treatment for the Asian population is lacking,” said Steven Thng Tien Guan, Deputy Director of NSC, NHG Health, and Consultant in-Charge of its Pigment Clinic.
The patients will be closely monitored for at least six months. Recruitment started this August and is expected to end by February 2026.
This real-world experience data collection will fill the knowledge gap,” he added.
Vitiligo is an autoimmune condition in which the immune system mistakenly attacks melanocytes, resulting in white patches on the skin.
In Singapore, the prevalence rate of vitiligo is approximately 7.4 per 1,000 population.